BACKGROUND: In a retrospective study of Southwestern Oncology Group (SWOG)-S8710/INT-0080 (radical cystectomy [RC] alone vs 3 cycles of neoadjuvant chemotherapy [NC] with methotrexate, vinblastine, doxorubicin, and cisplatin before RC for bladder cancer), factors found to be associated with improved overall survival (OS) included pathologic complete response, defined as P0; treatment with NC; completion of RC with negative surgical margins; and >or=10 pelvic lymph nodes (LNs) removed. METHODS: The authors used stratified Cox regression to retrospectively study the association of quality of pathologic response after RC with OS in the subset of S8710 patients who received NC and RC with negative surgical margins. RESULTS: Of 154 patients who received NC, 68 (44.2%) were <P2 (P0, Pa, P1, or carcinoma in situ [CIS]) at RC, 46 (29.9%) were P0, and the remainder had P2+ disease or did not undergo RC. In 115 patients who had RC with negative surgical margins, compared with P0 patients, those with residual Pa, P1, or CIS appeared to have worse OS (P=.054); OS was significantly worse for patients with residual P2+ disease (P=.0006). LN-positive (LN+) disease was found to be associated with worse OS than LN-negative (LN-) disease (P=.0005). Patients with LN- disease (ie, those with <10 LNs removed) appeared to have inferior OS compared with those with 10+ LNs removed (P=.079). The combination of pre-NC clinical stage and post-RC pathologic stage was found to be predictive of OS (P<.0001). CONCLUSIONS: NC and RC with negative surgical margins for bladder cancer followed by pathologic P0 and LN- disease were found to correlate with improved OS. A combination of baseline clinical stage and post-RC pathologic stage may better predict OS. Copyright (c) 2009 American Cancer Society.
BACKGROUND: In a retrospective study of Southwestern Oncology Group (SWOG)-S8710/INT-0080 (radical cystectomy [RC] alone vs 3 cycles of neoadjuvant chemotherapy [NC] with methotrexate, vinblastine, doxorubicin, and cisplatin before RC for bladder cancer), factors found to be associated with improved overall survival (OS) included pathologic complete response, defined as P0; treatment with NC; completion of RC with negative surgical margins; and >or=10 pelvic lymph nodes (LNs) removed. METHODS: The authors used stratified Cox regression to retrospectively study the association of quality of pathologic response after RC with OS in the subset of S8710 patients who received NC and RC with negative surgical margins. RESULTS: Of 154 patients who received NC, 68 (44.2%) were <P2 (P0, Pa, P1, or carcinoma in situ [CIS]) at RC, 46 (29.9%) were P0, and the remainder had P2+ disease or did not undergo RC. In 115 patients who had RC with negative surgical margins, compared with P0 patients, those with residual Pa, P1, or CIS appeared to have worse OS (P=.054); OS was significantly worse for patients with residual P2+ disease (P=.0006). LN-positive (LN+) disease was found to be associated with worse OS than LN-negative (LN-) disease (P=.0005). Patients with LN- disease (ie, those with <10 LNs removed) appeared to have inferior OS compared with those with 10+ LNs removed (P=.079). The combination of pre-NC clinical stage and post-RC pathologic stage was found to be predictive of OS (P<.0001). CONCLUSIONS: NC and RC with negative surgical margins for bladder cancer followed by pathologic P0 and LN- disease were found to correlate with improved OS. A combination of baseline clinical stage and post-RC pathologic stage may better predict OS. Copyright (c) 2009 American Cancer Society.
Authors: Ian C Smith; Steven D Heys; Andrew W Hutcheon; Iain D Miller; Simon Payne; Fiona J Gilbert; Antoinne K Ah-See; Oleg Eremin; Leslie G Walker; Tarun K Sarkar; S Peter Eggleton; Keith N Ogston Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: U E Studer; M Bacchi; C Biedermann; P Jaeger; R Kraft; L Mazzucchelli; R Markwalder; E Senn; R W Sonntag Journal: J Urol Date: 1994-07 Impact factor: 7.450
Authors: Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: D G Skinner; J R Daniels; C A Russell; G Lieskovsky; S D Boyd; P Nichols; W Kern; J Sakamoto; M Krailo; S Groshen Journal: J Urol Date: 1991-03 Impact factor: 7.450
Authors: Luca Boeri; Matteo Soligo; Igor Frank; Stephen A Boorjian; R Houston Thompson; Matthew Tollefson; Robert Tarrel; Fernando J Quevedo; John C Cheville; R Jeffrey Karnes Journal: World J Urol Date: 2019-02-25 Impact factor: 4.226
Authors: Derek E Thomas; Hristos Z Kaimakliotis; Kevin R Rice; Jose A Pereira; Paul Johnston; Marietta L Moore; Angela Reed; Dylan M Cregar; Cindy Franklin; Rhoda L Loman; Michael O Koch; Richard Bihrle; Richard S Foster; Timothy A Masterson; Thomas A Gardner; Chandru P Sundaram; Charles R Powell; Stephen D W Beck; David J Grignon; Liang Cheng; Costantine Albany; Noah M Hahn Journal: Clin Genitourin Cancer Date: 2016-11-30 Impact factor: 2.872
Authors: Adam C Reese; Mark W Ball; Nilay Gandhi; Michael A Gorin; George J Netto; Trinity J Bivalacqua; Mark P Schoenberg Journal: Urology Date: 2014-08 Impact factor: 2.649
Authors: Benjamin Miron; Jean H Hoffman-Censits; Fern Anari; John O'Neill; Daniel M Geynisman; Matthew R Zibelman; Alexander Kutikov; Rosalia Viterbo; Richard E Greenberg; David Chen; Costas D Lallas; Edouard J Trabulsi; R Katherine Alpaugh; Essel Dulaimi; Erica A Golemis; Robert Uzzo; Eric A Ross; Elizabeth R Plimack Journal: Eur Urol Oncol Date: 2020-03-10
Authors: Eliezer M Van Allen; Kent W Mouw; Philip Kim; Gopa Iyer; Nikhil Wagle; Hikmat Al-Ahmadie; Cong Zhu; Irina Ostrovnaya; Gregory V Kryukov; Kevin W O'Connor; John Sfakianos; Ilana Garcia-Grossman; Jaegil Kim; Elizabeth A Guancial; Richard Bambury; Samira Bahl; Namrata Gupta; Deborah Farlow; Angela Qu; Sabina Signoretti; Justine A Barletta; Victor Reuter; Jesse Boehm; Michael Lawrence; Gad Getz; Philip Kantoff; Bernard H Bochner; Toni K Choueiri; Dean F Bajorin; David B Solit; Stacey Gabriel; Alan D'Andrea; Levi A Garraway; Jonathan E Rosenberg Journal: Cancer Discov Date: 2014-08-05 Impact factor: 39.397